ArticleFrontiers in cardiovascular medicine2026
A protocol for the impact of Tongmai Jiangtang capsules on the risk of cardiovascular and cerebrovascular events in metabolic syndrome.
Article in Frontiers in cardiovascular medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06908473 (A Multicenter, Double-Blind, Randomized Controlled Study on the Impact of Tongmai Jiangtang Capsules on the Risk of Cardiovascular and Cerebrovascular Events in Metabolic Syndrome), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Multicenter, Double-Blind, Randomized Controlled Study on the Impact of Tongmai Jiangtang Capsules on the Risk of Cardiovascular and Cerebrovascular Events in Metabolic Syndrome
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
25 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Metabolic syndrome (MetS) significantly increases the risk of major adverse cardiovascular events (MACE), yet evidence-based complementary therapies remain limited. Tongmai Jiangtang Capsule (TJC), a traditional Chinese medicine (TCM) compound, has demonstrated benefits for glycolipid metabolism and microvascular complications, but its effect on hard cardiovascular and cerebrovascular (CCV) endpoints remains unconfirmed. Objective: To explore whether TJC, as an adjunctive therapy to standard care, reduces the incidence of MACE in patients with MetS and Qi deficiency-blood stasis syndrome. Methods: This is a randomized, double-blind, placebo-controlled, multicenter trial. A total of 530 participants aged ≥65 years, diagnosed with MetS and the TCM pattern of Qi Deficiency and Blood Stasis, and at high CCV risk, will be enrolled. They will be randomly assigned (1:1) to receive either TJC or a matched placebo, in addition to standard care, for 26 weeks, followed by a 26-week follow-up. The primary endpoint is the composite of 3P-MACE (cardiovascular death, non-fatal myocardial infarction, non-fatal stroke). Secondary endpoints include metabolic parameters, vascular assessments, TCM symptom scores, and quality of life. Omics analyses will explore potential mechanisms. The trial was registered on ClinicalTrials.gov (NCT06908473). Discussion: This rigorously designed trial is expected to provide high-level evidence regarding the role of TJC in preventing CCV events in MetS. If positive, it will offer a novel, multi-target integrative treatment strategy. The findings will also advance the evidence-based evaluation of TCM compounds and contribute to chronic disease prevention goals. Regardless of the primary outcome, the mechanistic insights will inform future research on formula optimization and precision intervention. Clinical Trial Registration: https://clinicaltrials.gov/expert-search?term=NCT06908473, identifier, NCT06908473.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.